Author/Authors :
Zhou، نويسنده , , Shengtao and Li، نويسنده , , Yuhua and Huang، نويسنده , , Fuqiang and Zhang، نويسنده , , Boya and Yi، نويسنده , , Tao and Li، نويسنده , , Zhengyu and Luo، نويسنده , , Hong and He، نويسنده , , Xiang-Xiang Zhong، نويسنده , , Qian and Bian، نويسنده , , Guang-Ce and Lin، نويسنده , , Xiaojuan and Qi، نويسنده , , Xiaorong and Liu، نويسنده , , Ping and Huang، نويسنده , , Canhua and Zhao، نويسنده , , Xia and Wei، نويسنده , , Yuquan، نويسنده ,
Abstract :
Herein we present a novel molecular mechanism of the antitumor effects of live-attenuated measles virus (MV) vaccine in ovarian cancer. Using a 2-DE/MS-based comparative proteomics strategy, we identified 17 proteins differentially expressed in live-attenuated MV vaccine-treated SKOV-3 ovarian cancer cells, including oxidative stress-associated enzymes and cell contact-related proteins, which indicated that live-attenuated MV vaccine could induce aberrant ROS activation. It further mediated epigenetic silencing of E-cadherin via upregulating DNMT3a that conferred both cell–cell and cell–matrix contact loss and apoptosis of ovarian cancer cells. This process could be reversed through ROS inhibition. Our study lays the theoretical foundation for the clinical application of live-attenuated MV vaccine as a potential oncotherapeutic agent for ovarian cancer treatment.
Keywords :
Ovarian cancer , Live-attenuated measles virus vaccine , PROTEOMICS , Anti-cancer effects
